Given the critical role of EGFR in cancer biology, targeting this receptor has emerged as a promising therapeutic strategy, particularly for patients diagnosed with HCC, in which EGFR overexpression or hyperactivation is frequently observed. The gene discussed is EGFR; the disease is cancer.